Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The Megacomplex protects ER-alpha from degradation by Fulvestrant in epithelial ovarian cancer

Cancer Letters(2024)10.1016/j.canlet.2024.217129Source: DataRank Database

The Megacomplex protects ER-alpha from degradation by Fulvestrant in epithelial ovarian cancer is a research paper published in Cancer Letters (2024). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

Linked data & code

pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.80)OA: hybridTopics (39)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Kevin Fedkenheuer ORCID,Ronak Khamar ORCID,Hua Tan ORCID,Valer Gotea ORCID,Sonam Raj ORCID

Live enrichment

PubMed:39048045 PMC:PMC12276986 OpenAlex:https://openalex.org/W4400881936

NCI

Grant: ZIA BC 011054

National Human Genome Research Institute

Grant: ZIA HG200323

Intramural NIH HHS

Grant: Z01 HG200323

National Human Genome Research Institute

FWCI

0.80

Citation Percentile

0.7%

Citation Trend

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.canlet.2024.217129

publisherhttps://doi.org/10.1016/j.canlet.2024.217129

publisherhttps://api.elsevier.com/content/article/PII:S030438352400524X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S030438352400524X?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39048045

Fields of Study

Protein Degradation and InhibitorsGenomics and Chromatin DynamicsPARP inhibition in cancer therapy

MeSH Terms

Carcinoma, Ovarian EpithelialFulvestrantAzepinesFemaleHumansOvarian NeoplasmsTriazolesAntineoplastic Agents, HormonalDrug Resistance, NeoplasmCell Line, TumorEstrogen Receptor alphaHepatocyte Nuclear Factor 3-alphaProteolysis

Keywords

FulvestrantEstrogen receptor alphaCancer researchChromatinBiologyEstrogen receptorOvarian cancerFOXA1Nuclear receptorCancerTranscription factorBiochemistryGeneGeneticsBreast cancerDrug resistancegel filtrationChip-seqJq1Super-enhancerIci182780MegacomplexBrd4 Inhibitor

Sustainable Development Goals

SDG 0: Zero hunger

The Megacomplex protects ER-alpha from degradation by Fulvestrant in epithelial ovarian cancer

FAIR Checklist

Authors (12)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)